Have a feature idea you'd love to see implemented? Let us know!

AVBP ArriVent BioPharma Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: AVBP

Price (delayed)

$26.59

Market cap

$896.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.65

Enterprise value

$613.37M

We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. We seek to utilize ...

Highlights
The EPS has soared by 72% YoY and by 34% from the previous quarter
AVBP's debt is down by 15% since the previous quarter
ArriVent BioPharma's quick ratio has decreased by 24% QoQ but it has increased by 13% YoY
The net income has declined by 38% year-on-year and by 8% since the previous quarter
The equity has contracted by 6% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.arrivent.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of AVBP
Market
Shares outstanding
33.7M
Market cap
$896.01M
Enterprise value
$613.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.22
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$81.05M
EBITDA
-$81.05M
Free cash flow
-$68.97M
Per share
EPS
-$9.65
Free cash flow per share
-$2.05
Book value per share
$8.26
Revenue per share
$0
TBVPS
$8.72
Balance sheet
Total assets
$292.71M
Total liabilities
$15.22M
Debt
$213,000
Equity
$277.49M
Working capital
$277.24M
Liquidity
Debt to equity
0
Current ratio
19.28
Quick ratio
18.66
Net debt/EBITDA
3.49
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-29.7%
Return on equity
-43.9%
Return on invested capital
N/A
Return on capital employed
-29.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVBP stock price

How has the ArriVent BioPharma stock price performed over time
Intraday
-2.99%
1 week
-5.31%
1 month
-7.38%
1 year
N/A
YTD
N/A
QTD
13.15%

Financial performance

How have ArriVent BioPharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$93.72M
Net income
-$81.05M
Gross margin
N/A
Net margin
N/A
ArriVent BioPharma's operating income has plunged by 51% YoY and by 9% from the previous quarter
The net income has declined by 38% year-on-year and by 8% since the previous quarter

Growth

What is ArriVent BioPharma's growth rate over time

Valuation

What is ArriVent BioPharma stock price valuation
P/E
N/A
P/B
3.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 72% YoY and by 34% from the previous quarter
The equity has contracted by 6% from the previous quarter

Efficiency

How efficient is ArriVent BioPharma business performance
ArriVent BioPharma's ROE has soared by 52% from the previous quarter
ArriVent BioPharma's ROA has increased by 8% YoY and by 2.6% from the previous quarter

Dividends

What is AVBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVBP.

Financial health

How did ArriVent BioPharma financials performed over time
ArriVent BioPharma's total assets has soared by 61% YoY but it has decreased by 5% from the previous quarter
The company's total liabilities has surged by 51% YoY and by 25% QoQ
AVBP's debt is 100% smaller than its equity
AVBP's debt is down by 15% since the previous quarter
The equity has contracted by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.